|
PRMT3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.046660E-04 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62458935193399E-12 |
| Stage1-vs-Stage2 |
1.114480E-02 |
| Stage1-vs-Stage3 |
4.138600E-01 |
| Stage1-vs-Stage4 |
8.37639999999862E-05 |
| Stage2-vs-Stage3 |
5.860700E-03 |
| Stage2-vs-Stage4 |
1.638130E-04 |
| Stage3-vs-Stage4 |
3.498400E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.64956936998806E-12 |
| Normal-vs-Asian |
1.62436730732907E-12 |
| Caucasian-vs-AfricanAmerican |
6.924000E-01 |
| Caucasian-vs-Asian |
9.377000E-01 |
| AfricanAmerican-vs-Asian |
7.922000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
9.414200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
2.98710000068425E-08 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.094600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.545230E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.537800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.638400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.022400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.085600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.096150E-03 |
| Classical-VS-Follicular |
4.10830000019402E-07 |
| Classical-VS-Other |
3.133600E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
9.63249480179229E-11 |
| Tall-VS-Other |
4.114800E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
3.033300E-04 |
| Follicular-VS-Normal |
3.36200000061737E-08 |
| Other-VS-Normal |
1.99850003212987E-09 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.62447832963153E-12 |
| N0-vs-N1 |
4.796100E-04 |
|
|
